Ann: Investor Presentation, page-236

First 236 Last

Share
Profile

Follow
truss20

1,020 Posts.

401

05/06/24

12:34

Post #: 74173887
Share

Originally posted by Blinger: ↑

Careful Truss, remember his big "discovery" of 320 (one died lol). plus we should remember the 4 in pilot prior to trial start.
So in fact 324 patients in OA alone.

So
1. GvHD P1 (15)
2. MEND (15 est.)
3. DFU (30)
4. OA (324)
5. GvHD P2 (20 est.) as 3 recruited in March in just 3 weeks, and start of trials always slower.
6. Renal (16 to be recruited but cells are already manufactured of course)

Looking around 420 as we speak.

Note: Mesoblast have only done 1 single arm trial in GvHD in over 10 years (54) Children
Cynata will surpass this number by end of year, if not by October in GvHD 15 + 60 (75) Adults

Cynata has officially treated more Adult GvHD patients in proper US trials than Mesoblast.

so agree
"Don't let the truth get in the way of your story though."

Expand

I'm sorry but this kind of research will not be tolerated around here. The only acceptable discourse is to say 'iPsC cAuSe CaNcEr' and 'MsB iS gReAt SuCceSs' (just ignore all the cash burn, debt covenants and 2 FDA rejections )

CYP Price at posting: 33.0¢ Sentiment: Buy Disclosure: Held
5 Upvote

0 Great analysis

Reply

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

RMX

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

BPH

Australia’s gas crisis is here – and dying coal plants aren’t helping

PAR

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

First 236 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 16.3¢		Change 0.008(4.84%)		Mkt cap ! $36.71M

Open	High	Low	Value	Volume
15.5¢	16.3¢	15.5¢	$25.19K	158.3K

Buyers (Bids)

No.	Vol.	Price($)
3	264481	16.0¢

Sellers (Offers)

Price($)	Vol.	No.
16.5¢	60674	2

View Market Depth

No.	Vol.	Price($)
3	354117	0.160
6	79833	0.155
5	161866	0.150
1	5000	0.145
2	45000	0.140

Price($)	Vol.	No.
0.165	60867	3
0.170	70193	3
0.175	64838	3
0.180	62619	3
0.185	45990	2

Last trade - 13.30pm 27/06/2025 (20 minute delay)

CYP (ASX) Chart

Ann: Investor Presentation, page-236

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Australia’s gas crisis is here – and dying coal plants aren’t helping

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Investor Presentation, page-236

Top Stories

Listen: HotCopper Wire Podcast 015 – Yeah, we're thinking the IPO market is back

Red Mountain: Chip samples point to 'large orogenic antimony mineral system' at Oaky Creek

Australia’s gas crisis is here – and dying coal plants aren’t helping

Paradigm Biopharmaceuticals makes key acquisition moving into FY26

NATO’s 5% target: Why Almonty Industries’ mega mine and NASDAQ listing are a perfect fit for investors

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News